Cargando…

Critical appraisal of the role of pegloticase in the management of gout

Gout is a debilitating disease secondary to chronic hyperuricemia, and the subsequent deposition of monosodium urate crystals is responsible for acute flare, gout arthropathies, tophi and renal lithiasis. Uric acid is the end product of purine metabolism in humans because the gene encoding uricase w...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ea, Hang-Korng, Richette, Pascal
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2012
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5045100/ https://www.ncbi.nlm.nih.gov/pubmed/27790013 http://dx.doi.org/10.2147/OARRR.S1743

Ejemplares similares

New advances in the treatment of gout: review of pegloticase
por: Reinders, Mattheus K, et al.
Publicado: (2010)

Pegloticase in Uncontrolled Gout: The Infusion Nurse Perspective
por: Baxter, Britni, et al.
Publicado: (2023)

Gout Treatment and Clinical Considerations: The Role of Pegloticase, Colchicine, and Febuxostat
por: Quintana, Michael J, et al.
Publicado: (2023)

Impact of pegloticase on patient outcomes in refractory gout: current perspectives
por: Cunha, Rita N, et al.
Publicado: (2018)

A Case Report of Successful Management of Refractory Polyarticular Gout With Pegloticase
por: Alnabwani, Dina, et al.
Publicado: (2022)

Simple Application and Adherence to Gout Guidelines Enables Disease Control: An Observational Study in French Referral Centres
por: Jauffret, Charlotte, et al.
Publicado: (2022)

Distribution of bony erosions in feet and performance of two bone erosion scores: A dual-energy computed tomography study of 61 patients with gout
por: Chabernaud Negrier, Amandine, et al.
Publicado: (2021)

Long-term safety of pegloticase in chronic gout refractory to conventional treatment
por: Becker, Michael A, et al.
Publicado: (2013)

Advances in the management of gout: Critical appraisal of febuxostat in the control of hyperuricemia
por: Beara-Lasic, Lada, et al.
Publicado: (2010)

Real-world patterns of pegloticase use for treatment of gout: descriptive multidatabase cohort study
por: Chen, Sarah K, et al.
Publicado: (2020)

Effect of Leflunomide on Pegloticase Response Rate in Patients with Uncontrolled Gout: A Retrospective Study
por: Masri, Karim Richard, et al.
Publicado: (2022)

Pegloticase immunogenicity: the relationship between efficacy and antibody development in patients treated for refractory chronic gout
por: Lipsky, Peter E, et al.
Publicado: (2014)

Retreatment with Pegloticase after a Gap in Therapy in Patients with Gout: A Report of Four Cases
por: Morton, Allan H., et al.
Publicado: (2018)

Frequency, distribution and immunologic nature of infusion reactions in subjects receiving pegloticase for chronic refractory gout
por: Calabrese, Leonard H., et al.
Publicado: (2017)

Infusion-Related Reactions With Pegloticase, a Recombinant Uricase for the Treatment of Chronic Gout Refractory to Conventional Therapy
por: Baraf, Herbert S. B., et al.
Publicado: (2014)

Tophus resolution in patients with chronic refractory gout who have persistent urate-lowering responses to pegloticase
por: Mandell, Brian F., et al.
Publicado: (2018)

Increased Efficacy and Tolerability of Pegloticase in Patients With Uncontrolled Gout Co-Treated With Methotrexate: A Retrospective Study
por: Albert, John A., et al.
Publicado: (2020)

Community Practice Experiences with a Variety of Immunomodulatory Agents Co-Administered with Pegloticase for the Treatment of Uncontrolled Gout
por: Broadwell, Aaron, et al.
Publicado: (2022)

Expert Opinion on Pegloticase with Concomitant Immunomodulatory Therapy in the Treatment of Uncontrolled Gout to Improve Efficacy, Safety, and Durability of Response
por: Botson, John K., et al.
Publicado: (2022)

Impact of comorbidities on gout and hyperuricaemia: an update on prevalence and treatment options
por: Bardin, Thomas, et al.
Publicado: (2017)

Efficacy and safety of lesinurad for the treatment of hyperuricemia in gout
por: Pérez-Ruiz, Fernando, et al.
Publicado: (2019)

Hyaluronan for knee osteoarthritis: an updated meta-analysis of trials with low risk of bias
por: Richette, Pascal, et al.
Publicado: (2015)

A Randomized, Placebo‐Controlled Study of Methotrexate to Increase Response Rates in Patients with Uncontrolled Gout Receiving Pegloticase: Primary Efficacy and Safety Findings
por: Botson, John K., et al.
Publicado: (2022)

Critical appraisal of the role of sorafenib in the management of hepatocellular carcinoma
por: Pan, Jen-Jung, et al.
Publicado: (2010)

PEG-ing down (and preventing?) the cause of pegloticase failure
por: Abeles, Aryeh M
Publicado: (2014)

Tophus burden reduction with pegloticase: results from phase 3 randomized trials and open-label extension in patients with chronic gout refractory to conventional therapy
por: Baraf, Herbert SB, et al.
Publicado: (2013)

Preventing and managing exacerbations in COPD – critical appraisal of the role of tiotropium
por: Tashkin, Donald P
Publicado: (2010)

Critical appraisal of lurasidone in the management of schizophrenia
por: Caccia, Silvio, et al.
Publicado: (2012)

Proprotein convertase furin inhibits matrix metalloproteinase 13 in a TGFβ-dependent manner and limits osteoarthritis in mice
por: Lin, Hilène, et al.
Publicado: (2018)

Induced and pre-existing anti-polyethylene glycol antibody in a trial of every 3-week dosing of pegloticase for refractory gout, including in organ transplant recipients
por: Hershfield, Michael S, et al.
Publicado: (2014)

Lin28a induces SOX9 and chondrocyte reprogramming via HMGA2 and blunts cartilage loss in mice
por: Jouan, Yohan, et al.
Publicado: (2022)

Transdermal buprenorphine – a critical appraisal of its role in pain management
por: Hans, Guy, et al.
Publicado: (2009)

Is there a role for cherries in the management of gout?
por: Collins, Marcum W., et al.
Publicado: (2019)

Tophus resolution with pegloticase: a prospective dual-energy CT study
por: Araujo, Elizabeth G, et al.
Publicado: (2015)

High Rate of Adherence to Urate-Lowering Treatment in Patients with Gout: Who’s to Blame?
por: Perez-Ruiz, Fernando, et al.
Publicado: (2020)

A critical appraisal of atomoxetine in the management of ADHD
por: Childress, Ann C
Publicado: (2015)

Computational Lexical Analysis of the Language Commonly Used to Describe Gout
por: Lawrence Edwards, N., et al.
Publicado: (2016)

Improved joint and patient-reported health assessments with pegloticase plus methotrexate co-therapy in patients with uncontrolled gout: 12-month exploratory outcomes of the MIRROR open-label trial
por: Botson, John K., et al.
Publicado: (2022)

A Randomized, Double‐Blind, Placebo‐Controlled Multicenter Efficacy and Safety Study of Methotrexate to Increase Response Rates in Patients With Uncontrolled Gout Receiving Pegloticase: 12‐Month Findings
por: Botson, John K., et al.
Publicado: (2023)

Biomedical waste management in India: Critical appraisal
por: Datta, Priya, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_f6l1jloebrvaodcuhjpp0n4244